MedTrace Logo

Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

NCT04748601 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2025-01-27

No results posted yet for this study

Summary

A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.

Conditions

  • Migraine Disorders

Interventions

DRUG

Qudexy XR

Extended-Release Capsule

DRUG

Placebo

Qudexy XR Matching capsules

Sponsors & Collaborators

  • Upsher-Smith Laboratories

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-19
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04748601 on ClinicalTrials.gov